Product Name: Cefoselis sulfate
Synonyms: (6R-(6alpha,7beta(Z)))-7-(((2-Amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-((2,3-dihydro-2-(2-hydroxyethyl)-3-imino-1H-pyrazol-1-yl)methyl)-8-oxo-5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid sulfate;Winsef;CEFOSELIS SULFATE;FK 037;(6R,7R,E)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-((2-(2-hydroxyethyl)-3-imino-2,3-dihydropyrazol-1-yl)methyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid, sulfate;FK 037 Sulfate
CAS: 122841-12-7
MF: C19H24N8O10S3
MW: 620.64
EINECS: 1533716-785-6
Product Categories: Cefoselis sulfate and its intermediates;Inhibitors
Mol File: 122841-12-7.mol
Cefoselis sulfate Structure
Cefoselis sulfate Chemical Properties
CAS DataBase Reference 122841-12-7(CAS DataBase Reference)
Safety Information
MSDS Information
Cefoselis sulfate Usage And Synthesis
Description Cefoselis is a new fourth-generation cephalosporin and was launched in Japan as a parenteral antibiotic for a variety of infections including Staphylococcus aureus (particularly the methicillin-resistant MRSA) and Pseudornonas aeruginosa. It can be prepared in 3 related ways, all using 2- pyrazolomethyl-3-cephem-4-carboxylic as the key intermediate. In preclinical studies, Cefolesis had better MIC50s than Ceftazidime against Streptococcus pneurnoniae or Staphflococcus aureus (methicillin-sensitive MSSA or resistant MRSA) and showed significant antibacterial activity against Citrobacter and Enterobacter.
Cefolesis is well tolerated in clinical studies, being eliminated mainly via glomerular filtration in humans.
Originator Fujisawa (Japan)
Uses antibiotic
Brand name Wincef
China
